Treatment gaps for opioid use disorder among commercially insured US surgical patients, 2016–2022
Authors' conclusion
In this national cohort of commercially insured surgical patients, most individuals diagnosed with OUD did not receive evidence-based treatment before surgery, despite modest improvements over time.
Study context
- Population
- US adults aged 18–64 years undergoing inpatient or outpatient surgery, commercially insured, July 2016 to December 202262.5% female
- Participants
- 5,341,768 adults
- Outcome
- OUD diagnosis and MOUD receipt (buprenorphine, methadone or naltrexone) within 180 days before surgery
Methodological detailsnational claims database (Merative MarketScan Commercial)
- National claims database (Merative MarketScan Commercial)
Main finding
As reported in the abstract
OUD diagnosis and MOUD receipt
- Opioid use disorder (OUD) diagnosis, overall
- 31 094 (0.58%)
- OUD prevalence, 2016
- 0.71%
- OUD prevalence, 2022
- 0.50%
- Medications for opioid use disorder (MOUD) receipt in 6 months before surgery among OUD, 2016
- 17.8%
- MOUD receipt in 6 months before surgery among OUD, 2022
- 32.6%
- Treatment gap in MOUD receipt, 2016
- 82.2%
- Treatment gap in MOUD receipt, 2022
- 67.4%
Observational data: associations, not effects.
Original publication
Treatment gaps for opioid use disorder among commercially insured US surgical patients, 2016–2022. Reg Anesth Pain Med. Published 19 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →